HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Affirms M&A Strategy For Consumer Biz With Vogue International Buy

This article was originally published in The Rose Sheet

Executive Summary

Johnson & Johnson wins a reported bidding war for Vogue International, picking up the popular OGX brand and other "salon-heritage" hair-care lines with natural overtones. The move is consistent with the firm's stated intention to grow its consumer business in part through targeted M&A.

You may also be interested in...



J&J's CEO Gorsky Steps Aside With Duato Named His Successor

J&J's CEO Alex Gorsky is stepping down after almost 10 years in the role and will be replaced by vice chairman of the executive committee Joaquin Duato. 

J&J’s Aveeno Hair-Care Relaunch Per Vogue Model Helps Drive Consumer Q2 Improvements

Company leadership has said that Vogue International – the maker of OGX and Maui Moisture hair care that J&J acquired in 2016 – would serve as a model for innovations across other brands. Strategy appears to be paying off, contributing to gains in J&J's Consumer division, which also benefited in the second quarter from Zyrtec allergy treatment and children’s Tylenol and Motrin.

Baby, Hair Care Pose As Models For J&J Consumer Health Business

J&J's Vogue hair care brand has the “agile, fast, flexible mindset” the firm looks to emulate across its other consumer brands, says CEO Alex Gorsky says at the J.P. Morgan Healthcare Conference. However, that strategy will be a challenge for sun care, where the firm does not want to sacrifice valuable science.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS019938

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel